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Publique- Hôpitaux de Paris) (AP-HP), 83, boulevard de l’Hôpital, 75013 Paris, France. Tel þ 33 01 42 16 29 62, E-mail: jean-philippe.collet@aphp.fr; Holger Thiele, Department
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Biomarkers and differential
diagnosis
Q1. You are on rounds in the emergency department and
your intern asks you: what is the main difference between
non-ST-segment elevation myocardial infarction (NSTEMI)
and unstable angina?
NSTEMI is characterized by ischaemic symptoms associated with acute car-
diomyocyte injury (¼rise and/or fall in cardiac troponin T/I), while ischaemic
symptoms at rest (or minimal effort) in the absence of acute cardiomyocyte
injury define unstable angina. This translates into an increased risk of death
in NSTEMI patients, while unstable angina patients are at relatively low
short-term risk of death (sections 3.3.1 and 3.3.2, Figure 1).
Q2. A 72-year-old patient with hypertension and hypercho-
lesterolaemia as cardiovascular risk factors (CVRF)
presents to the emergency department with typical chest
pain of 3 h duration, palpitations, atrial fibrillation with a
ventricular rate of about 120 beats per minute, ST depres-
sion on electrocardiogram (ECG), and a mild elevation in
cardiac troponin (cTn) (twice the upper limit of normal
[ULN]). Is it correct to state that the underlying process is
a rupture, ulceration, fissuring, or erosion of a coronary
atherosclerotic plaque?
No. According to the universal definition of myocardial infarction (MI), two
main subtypes of NSTEMI have to be differentiated: type 1 MI, character-
ized by any of the processes just previously described, and type 2 MI, in
which an extra-coronary condition is the main cause of imbalance between
myocardial oxygen supply and demand (e.g. tachycardia, anaemia, hyper-
tension, or hypotension). The patient described may have had both (sections
3.3.1 and 3.3.2, Figure 1).
Q3. Which are the three mandatory diagnostic corner-
stones of the early diagnosis of non-ST-elevation acute coro-
nary syndrome (NSTEMI) among the following: past
clinical history including a detailed description of the chest
pain characteristics, 12-lead ECG, chest X-ray, elevated
and dynamic rise in cTn, treadmill test, computed tomog-
raphy (CT) angiography, and myocardial perfusion scan?
Early diagnosis of NSTEMI relies on clinical assessment (i.e. past clinical his-
tory including a detailed description of the chest pain characteristics), 12-
lead ECG, and cTn (sections 3.3 and 3.3.2, Figure 1).
Q4. You are challenged by a new cardiology fellow regard-
ing the cTn assay used in your institution. She states that
current ESC guidelines recommend using a high-sensitivity
cTn (hs-cTn) assay and that your current assay is not high-
sensitivity. What are the advantages of hs-cTn?
Hs-cTn measurements are recommended over less sensitive ones, as they
provide higher diagnostic accuracy at identical low cost. The higher diagnos-
tic accuracy mainly translates into the possibility for earlier and safer rule-
out of MI, and therefore shorter length of stay in the emergency depart-
ment and lower treatment cost (which are mainly determined by the time
in the emergency department) (section 3.3.2, Figure 2).
Q5. You plan to introduce the measurement of hs-cTn in
your hospital. A fellow asks: what will the impact be on the
diagnosis of NSTEMI and unstable angina in patients pre-
senting to the emergency department with acute chest
pain?
With the introduction of hs-cTn there will be some increase in the preva-
lence of NSTEMI and a reciprocal decrease in the incidence of unstable
angina. The percentage of reclassified patients depends on the difference in
sensitivity between the current and the new assay. If the current assay has
low sensitivity and is a ‘conventional’ cTn assay, an increase in NSTEMI diag-
noses is to be expected by approximately 4% absolute and 20% relative,
with a corresponding decrease in unstable angina. If the current assay is
already a sensitive cTn assay, then the percentage of reclassified patients
will be smaller (e.g. 12% absolute, 510% relative) (section 3.3.2,
Figure 2).
Q6. You are called by a fellow from the emergency
department regarding an 85-year-old patient presenting
with a hip fracture following a fall. For unknown reasons,
cTn has been measured and the concentration is twice
the upper limit of normal. The 12-lead ECG is normal. He
said that the elevated cTn allows him to diagnose
NSTEMI and asks for the need for early invasive coronary
angiography.
It is very unlikely that NSTEMI is the correct diagnosis in this patient.
Accordingly, there is no need for early invasive coronary angiography. A mild
and probable constant and chronic cTn elevation is common in the elderly
patient and a reflection of the pre-existing cardiac disease (known or
unknown to the patient), resulting in chronic cardiomyocyte injury (section 3.
3.2, Figure 2).
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Q7. A 50-year-old patient with no relevant past medical his-
tory presents with persistent severe retrosternal chest pain
radiating to both shoulders and arms which started 4 h ear-
lier. Haemodynamic status is stable and the initial physical
examination is unremarkable. The 12-lead ECG is normal.
The initial hs-cTn T concentration is 300 ng/L (ULN < 14
ng/L). Is it possible to make a clear working diagnosis or do
you need a second hs-cTn measurement?
There is no need for a second troponin assessment. The diagnosis of
NSTEMI is made and appropriate treatment should be initiated. The posi-
tive predictive value for NSTEMI in patients with typical symptoms and a
substantial (> 20 times the 99th percentile) elevation in cTn is > 90%
(section 3.3.3). If the institution uses the ESC hs-cTn T 0h/1 h-algorithm, an
initial hs-cTn T concentration above 52 ng/L allows triage of patients
towards rule-in (section 3.3.3, Figure 3, Table 5).
The next four scenarii highlight how to use the available different types of
hs-cTn.
Q8. A 60-year-old patient without prior history of coronary
artery disease (CAD) presents to the emergency depart-
ment with recurrent right-sided thoracic chest pain. The
last chest pain episode started 5 h prior to hospital admis-
sion and is still ongoing. He is haemodynamically stable and
the physical examination is normal. The 12-lead ECG is
also normal. The initial hs-cTn T level is normal at 4 ng/L
(ULN < 14 ng/L). The intern in the emergency department
asks you as a cardiology consultant if this single very low hs-
cTn T concentration allows the rule-out of NSTEMI.
Yes. As the patient presented more than 3 h after chest pain onset, the sin-
gle measurement rule-out pathway of the ESC hs-cTn T 0h/1 h-algorithm
can be applied, which allows the rapid and safe triage towards rule-out of
NSTEMI if the hs-cTn T concentration is < 5 ng/L. The negative predictive
value for the rapid rule-out of NSTEMI in this setting is > 99.5%. Most of
these patients are also excellent candidates for rapid discharge and outpa-
tient management, possibly including non-invasive stress testing (preferably
with imaging) (section 3.3.3, Figure 3, Table 5).
Q9. A 60-year-old patient without prior history of CAD
presents to the emergency department with recurrent
right-sided thoracic chest pain. The last chest pain episode
started 5 h prior to hospital admission and is still ongoing.
He is haemodynamically stable and the physical examina-
tion is normal. The 12-lead ECG is also normal. The initial
hs-cTn I (Architect) level is normal at 2 ng/L (ULN < 26 ng/
L). The intern in the emergency department asks you as a
cardiology consultant if this single very low hs-cTn I
Architect concentration allows the rule-out of NSTEMI.
Yes. As the patient presented more than 3 h after chest pain onset, the sin-
gle measurement rule-out pathway of the ESC hs-cTn I Architect 0 h/1 h-
algorithm can be applied, which allows the rapid and safe triage towards
rule-out of NSTEMI if the hs-cTn I concentration is < 4 ng/L. The negative
predictive value for the rapid rule-out of NSTEMI in this setting is> 99.5%.
Most of these patients are also excellent candidates for rapid discharge
and outpatient management, possibly including non-invasive stress testing
(preferably with imaging) (section 3.3.3, Figure 3, Table 5).
Q10. A 60-year-old patient without prior history of CAD
presents to the emergency department with recurrent
right-sided thoracic chest pain. The last chest pain episode
started 5 h prior to hospital admission and is still ongoing.
He is haemodynamically stable and the physical examina-
tion is normal. The 12-lead ECG is also normal. The initial
hs-cTn I Centaur level is normal at 2 ng/L (ULN < 47 ng/L).
The intern in the emergency department asks you as a car-
diology consultant if this single very low hs-cTn I Centaur
concentration allows the rule-out of NSTEMI.
Yes. As the patient presented more than 3 h after chest pain onset, the sin-
gle measurement rule-out pathway of the ESC hs-cTn I Centaur 0 h/1 h-
algorithm can be applied, which allows the rapid and safe triage towards
rule-out of NSTEMI if the hs-cTn I Centaur concentration is < 3 ng/L. The
negative predictive value for the rapid rule-out of NSTEMI in this setting is
> 99.5%. Most of these patients are also excellent candidates for rapid dis-
charge and outpatient management, possibly including non-invasive stress
testing (preferably with imaging) (section 3.3.3, Figure 3, Table 5).
Q11. A 60-year-old patient without prior history of CAD
presents to the emergency department with recurrent
right-sided thoracic chest pain. The last chest pain episode
started 5 h prior to hospital admission and is still ongoing.
He is haemodynamically stable and the physical examina-
tion is normal. The 12-lead ECG is also normal. The initial
hs-cTn I Access level is normal at 3 ng/L (ULN < 18 ng/L).
The intern in the emergency department asks you as a car-
diology consultant if this single very low hs-cTn I Access
concentration allows the rule-out of NSTEMI.
Yes. As the patient presented more than 3 h after chest pain onset, the sin-
gle measurement rule-out pathway of the ESC hs-cTn I Access 0 h/1 h-algo-
rithm can be applied, which allows the rapid and safe triage towards rule-
out of NSTEMI if the hs-cTn I Access concentration is < 4 ng/L. The nega-
tive predictive value for the rapid rule-out of NSTEMI in this setting is >
99.5%. Most of these patients are also excellent candidates for rapid dis-
charge and outpatient management, possibly including non-invasive stress
testing (preferably with imaging) (section 3.3.3, Figures 3 and 4, Table 5).
Q12. A 60-year-old patient without prior history of CAD
presents to the emergency department with recurrent
right-sided thoracic chest pain. The last chest pain episode
started 5 h prior to hospital admission and is still ongoing.
He is haemodynamically stable and the physical examina-
tion is normal. The 12-lead ECG is also normal. The initial
hs-cTn I Vitros level is normal at 0.7 ng/L (ULN < 11 ng/L).
The intern in the emergency department asks you as a car-
diology consultant if this single very low hs-cTn I Vitros con-
centration allows the rule-out of NSTEMI.
Yes. As the patient presented more than 3 h after chest pain onset, the sin-
gle measurement rule-out pathway of the ESC hs-cTn I Vitros 0 h/1 h-algo-
rithm can be applied, which allows the rapid and safe triage towards rule-
out of NSTEMI if the hs-cTn I Vitros concentration is< 1 ng/L. The negative
predictive value for the rapid rule-out of NSTEMI in this setting is> 99.5%.
Most of these patients are also excellent candidates for rapid discharge
and outpatient management, possibly including non-invasive stress testing
(preferably with imaging) (section 3.3.3, Figure 3, Table 5).
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Q13. A 60-year-old patient without prior history of CAD
presents to the emergency department with intermittent
recurrent moderate right-sided thoracic chest pain without
radiation over the last 2 days. The last chest pain episode
started 2 h prior to hospital admission and lasted for 30
min. He is haemodynamically stable and the physical
examination is normal. The 12-lead ECG is also normal.
The initial hs-cTn T level is normal at 4 ng/L (ULN
<14 ng/L). The intern in the emergency department asks you
as a cardiology consultant if the patient can be discharged.
No. As the patient presented very early after chest pain onset, the intern
needs to wait for the second cTn measurement at 1 h if using the ESC hs-
cTn T 0 h/1 h-algorithm or at 2 h if using the ESC hs-cTn T 0 h/2 h-algo-
rithm. If the second measurement is also within normal limits and there is
NO relevant change to the measurement at presentation, NSTEMI can be
reliably ruled-out and the patient is to be considered at low risk of cardiac
events. From a cardiology perspective, he may then be discharged home. If
no clear alternative explanation such as, for example, musculoskeletal
chest pain or bronchitis is found to explain the patient’s symptoms, he may
undergo non-invasive stress testing (preferably with imaging) on an outpa-
tient basis (section 3.3.3, Table 5, Figure 3).
Q14. A 60-year-old patient with a history of CAD presents
to the emergency department with chest pain and cough
lasting for 2 days. The right-sided thoracic chest pain is per-
sistent, moderate in intensity, non-radiating, and increases
in intensity during inspiration. The last episode of chest
pain started 8 h prior to admission and the patient is still
mildly symptomatic in the emergency department. He is
haemodynamically stable and the physical examination is
unremarkable. The 12-lead ECG shows T-wave inversion in
lead I and aVL, which were already noted in the ECG per-
formed last year. The initial hs-cTn I Architect concentra-
tion is very low/undetectable at 2 ng/L (ULN < 26 ng/L).
The emergency department intern, a bright young physi-
cian who wants to become a cardiologist, challenges you by
saying that ‘it is obvious that the chest pain does not repre-
sent acute MI and no additional investigations or blood
tests in this respect are needed’. Is she right?
Yes. NSTEMI, based on the delay between symptom onset and blood test,
can be reliably ruled-out with a single very low level of hs-cTn T/I. In addition,
unstable angina is extremely unlikely since prolonged ischaemia is expected
to lead to some degree of cTn elevation. An alternative diagnosis such
as pneumonia/bronchitis should be considered (section 3.3.3, Tables 4 and
5, Figure 3).
Q15. You are supervising the emergency department/chest
pain unit (CPU) and see an 80-year-old patient with a his-
tory of CAD, prior MI, and hypertensive heart disease pre-
senting with persistent moderate right-sided thoracic chest
pain ongoing for 7 h that increases in intensity during exer-
cise and inspiration. In addition, he has mild fever and an
increasing productive cough over the last 3 days. He is hae-
modynamically stable and the initial physical examination
reveals rales over the base of the right lung. ECG shows T-
wave inversion in V3V6, which were already noted on the
ECG performed 3 years ago. A chest X-ray shows an infil-
trate in the right lung suggestive of pneumonia. Your intern
is about to order blood cultures (plus legionella and pneu-
mococcus antigen in the urine) and prescribe antibiotics
when the hs-cTn T level is reported from the laboratory as
elevated. Your intern now asks you if the patient needs
treatment for pneumonia, NSTEMI, or both.
This patient has a high likelihood for pneumonia and a low likelihood for
NSTEMI. To answer the question whether he has concomitant NSTEMI,
you need to know the exact value of hs-cTn at presentation as well as the
dynamics after 1 h or 2 h. If the hs-cTn levels are only mildly elevated (e.g.
according to the assay 18 ng/L if ULN is 14 ng/L), then the mild elevation in
hs-cTn in this specific patient can be attributed to cardiac causes other than
NSTEMI (e.g. pre-existing CAD/MI or hypertensive heart disease plus some
degree of cardiomyocyte injury related to sepsis/pneumonia) and no specific
treatment is needed. A rise or fall in hs-cTn is required for the diagnosis of
NSTEMI, and most NSTEMIs have higher concentrations 7 h after the
onset of acute chest pain (section 3.3.3, Figures 3 and 4, Tables 4 and 5).
Q16. You are the cardiology consultant responsible for the
training of residents starting their rotation in the emer-
gency department. When discussing patient pathways, a
resident asks you whether the majority of patients present-
ing with acute chest pain to the emergency department
ultimately require hospitalization to reliably rule-out or
rule-in acute MI (AMI).
No. Using either a hs-cTn T/I 0 h / 1 h-algorithm or a hs-cTn T/I 0h/2 h-algo-
rithm, the majority of patients (75%) can be reliably ruled-out or ruled-in
within the first hours in the emergency department (sections 3.3.2 and
3.3.3). Ultimately, the majority of patients (> 60%) can be discharged after
rapid rule-out of AMI and managed as outpatients using these algorithms
(section 3.3.3, Figure 3, Table 5).
Q17. You are supervising the emergency department/CPU.
A resident questions you regarding the further manage-
ment of a 60-year-old woman with a history of CAD pre-
senting with ongoing moderate left-sided thoracic chest
pain without radiation that started 2 h prior to admission
and resolved spontaneously in the emergency department.
She is haemodynamically stable and the physical examina-
tion and 12-lead ECG are unremarkable. Levels of hs-cTn T
assessed at presentation and 1 h were normal and identical
at 7 ng/L (ULN < 14 ng/L). Can NSTEMI be ruled-out?
Yes, the negative predictive value for MI in patients classified as ‘rule-out’ by
the hs-cTn T 0 h/1 h-algorithm is 99100%. Used in conjunction with clini-
cal assessment and the 12-lead ECG as mandatory additional sources of
information, the 0 h/1 h-algorithm allows the early rule-out of MI and early
detection of patients that are candidates for outpatient management (i.e.
no further investigation or non-invasive imaging). It is important to highlight
that prior to discharge, other life-threatening causes of acute chest pain,
such as aortic dissection, pulmonary embolism, and tension pneumothorax,
need to be considered (section 3.3.3, Figures 3 and 4, Tables 4 and 5).
Q18. You are supervising the emergency department/CPU.
A resident asks you about the further management of a 64-
year-old woman without CVRFs and without known CAD
4 ESC Guidelines
D
ow
nloaded from
 https://academ
ic.oup.com
/eurheartj/advance-article/doi/10.1093/eurheartj/ehaa602/5898618 by guest on 20 N
ovem
ber 2020
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
.
presenting with moderate retrosternal chest pain without
radiation that started 3 h prior to admission and lasted for
1 h. She is haemodynamically stable, pain free, and the
physical examination as well as the 12-lead ECG are nor-
mal. Levels of hs-cTn I Architect at presentation are 100
ng/L (ULN < 26 ng/L). Your intern is using the assay-specific
ESC 0 h/1 h-algorithm you just introduced in the hospital
and he tells you that according to the algorithm the patient
can be ‘ruled-in’. Now the intern wants to know what it
means: does the patient have NSTEMI?
The positive predictive value for MI in patients classified as ‘rule-in’ by the
hs-cTn T 0 h/1 h-algorithm is 7080%. Used in conjunction with clinical
assessment and the 12-lead ECG  mandatory additional sources of infor-
mation  the 0 h/1 h-algorithm allows the early detection of patients who
are candidates for early invasive coronary angiography, particularly as most
of the rule-in patients with a diagnosis other than acute MI will have condi-
tions that also usually require inpatient coronary angiography for accurate
diagnosis, including Takotsubo syndrome, myocarditis, and unstable angina.
This patient should undergo early invasive coronary angiography (section 3.
3.3, Figure 3, Table 4).
Q19. The measurement of hs-cTn T/I is mandatory in all
patients presenting with suspected NSTE-ACS. Is it neces-
sary to routinely measure other cardiovascular biomarkers
in addition to hs-cTn T/I? If yes, which ones?
It is NOT necessary to routinely measure other cardiovascular biomarkers
in addition to hs-cTn T/I (section 3.3.2).
Q20. Your colleague from the emergency room asks you if
adding copeptin to the blood sample of a patient arriving
with acute chest pain might help for the early rule-out of
MI.
The added value of copeptin depends on the sensitivity of the cTn assay
used. If using a cTn assay with poor sensitivity, copeptin does provide incre-
mental diagnostic value and is advised as an aid for the rapid rule-out of MI
within a dual marker strategy. However, if using, as recommended in the
ESC Guidelines, a hs-cTn T/I assay within a hs-cTn T/I 0 h/1 h-algorithm or
hs-cTn T/I 0 h/2 h-algorithm, copeptin does not have added value and
should not be used (section 3.3.2.2).
Q21. Your fellow asks you if B-type natriuretic peptide
(BNP) may help in the diagnosis of patients with suspected
MI.
No, BNP does not help in the diagnosis. However, it provides important
prognostic information for death and/or the development of heart failure,
particularly in patients with established NSTE-ACS (section 3.3.2.2).
Q22. A point-of-care test (POCT) has been set up in the
emergency department. Your colleague asks you if he can
use one of the ESC hs-cTn T/I 0 h/1 h-algorithms for rule-in/
rule-out of NSTEMI in patients presenting with acute chest
pain.
Most likely, this is not possible. The new ESC hs-cTn T/I 0 h/1 h-algorithms
for rule-in/rule-out of NSTEMI in patients presenting with acute chest pain
can only be used with hs-cTn T/I assays. Unfortunately, the vast majority of
current POCTs do have poor sensitivity and cannot be used for rapid rule-
out/rule-in protocols. However, there is one exception and others are in
development (section 3.3.2.1).
Q23. A 69-year-old woman with a past medical history of
thoracic radiotherapy for breast cancer and diabetes melli-
tus on glucagon-like peptide 1 (GLP1) agonist therapy is
admitted to the emergency department for acute retro-
sternal chest pain with radiation to the left arm. She
remains in pain despite sublingual nitrates. The physical
examination is normal. The 12-lead ECG shows 3 mm ST-
segment depression in leads V2V6, I, and aVL. The emer-
gency department physician asks you whether the patient
should undergo coronary angiography right now or
whether she has to wait for the results of the first cTn
measurement, which are expected to come back from the
lab in about 45 minutes.
Given the very high likelihood of ongoing myocardial ischaemia, and the
large myocardial territory at risk, the patient should undergo immediate
invasive coronary angiography (section 3.3.1, Figure 9).
Risk assessment
Q24. You are working in the emergency department on
Friday at 9 pm. A new patient (male, 77 years) arrives with
de-novo angina at minimal exertion, which started 3 days
ago. The ECG on admission excludes a STEMI and shows
no other ST-segment alterations. The laboratory studies
reveal normal levels for hs-cTn at presentation and 1 h
thereafter as well as a serum creatinine level of 102 mmol/L.
The patient is haemodynamically stable (systolic blood
pressure 115 mmHg, heart rate 82 beats per min [bpm])
but has rales in the basal portion of both lungs (i.e. Killip
class II). Life-threatening arrhythmias are not documented.
Your colleague states that you can transfer the patient to
the ward and sign him on invasive coronary angiography for
Monday. Is he right?
No. You should calculate the GRACE [Global Registry of Acute Coronary
Events ] risk score because subgroup analyses of two major trials indicated
that patients with a high risk for in-hospital death, according to the original
GRACE risk score published by Granger et al (i.e. > 140 points) (https://
www.outcomes-umassmed.org/risk_models_grace_orig.aspx for the
GRACE risk score 1.0 and https://www.outcomes-umassmed.org/
grace/acs_risk2/index.html for the GRACE risk score 2.0), may do bet-
ter with an early invasive strategy as compared to a delayed invasive strat-
egy. The GRACE risk score is 154 points for this patient. Therefore,
according to guidelines an invasive coronary angiography within 24 h should
be performed and you should schedule the patient for Saturday (< 24 h
from now) (section 4.3, Figure 9).
Q25. Two hours later, another patient (female, 75 years)
enters the emergency department because she experi-
enced chest pain at rest for around 35 minutes earlier in
the day. The patient is haemodynamically stable, has no
life-threatening arrhythmias, and no ST-segment elevation
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is documented. The hs-cTn level is 52 and 68 ng/L (ULN 14
ng/L) at presentation and 1 h later (ESC 0 h/1 h-algorithm
rule-in path). Your colleague gets enthusiastic about the
GRACE risk score that is 129 based on the following crite-
ria: Killip class I, systolic blood pressure 145 mmHg, heart
rate 72 bpm, serum creatinine level 79 mmol/L, no ST-
segment alterations, no cardiac arrest before admission.
Your colleague states that the workload for the interven-
tional cardiologist on duty can be limited because the
patient can wait until Monday morning (GRACE risk score
not above 140 points). Is he correct this time?
No. The patient’s hs-cTn T level is elevated with a rise compatible with MI. This
is a high-risk criterion irrespective of the GRACE risk score; therefore, the
patient should also undergo invasive coronary angiography within 24 h (i.e.
Saturday and not Monday). However, risk prediction is recommended irrespec-
tive of the timing decision. Short- and long-term ischaemic risk can be accu-
rately and conveniently assessed using the GRACE 2.0 web calculator.
Objective risk assessment by means of the GRACE risk score has proven supe-
rior over subjective assessment done by the physician (section 4.3, Figure 9).
Q26. Following your expertise on ischaemic risk prediction,
your colleague then asks you whether similar scores have
been developed regarding the risk for major bleeding.
Yes, there are also bleeding risk scores. However, their clinical utility is chal-
lenged by the overlap between bleeding and ischaemic risk factors and the
overall modest accuracy of the bleeding risk scores. However, these risk
scores (e.g. CRUSADE) may still be useful to inform clinicians and patients
(section 4.3).
Non-invasive imaging
Q27. A 48-year-old man with a history of dyslipidaemia is
referred to the emergency department because of acute
chest pain with radiation to his shoulders and arms. This
was accompanied by heavy sweating and nausea which
lasted for 30 minutes, starting after his lunch, now 4 h ago.
At first medical contact, the patient was pain free and the
physical examination was unremarkable. The 12-lead ECG
indicates no ST and/or Twave abnormalities. The initial as
well as the 1 h follow-up level of hs-cTn is below the ULN
without a significant dynamic change. The GRACE risk
score is 59. The emergency department physician asks the
cardiology fellow on call whether an invasive or non-
invasive coronary assessment should follow.
Further investigations depend on patient and test characteristics, as well as
local setting and expertise. The patient belongs to the low-risk group with a
GRACE risk score of 59, indicative of< 3% risk of death up to 6 months fol-
lowing the index event. Therefore, a non-invasive assessment is recom-
mended, e.g. functional testing by stress echocardiography or cardiac
magnetic resonance (CMR) imaging or anatomic imaging by coronary CT
angiography (CCTA) (sections 3.3.3 and 3.3.5, Figures 3 and 4, Table 6).
Q28. The emergency department physician decided to per-
form CCTA to exclude obstructive CAD. Your fellow would
like to know whether this strategy is in accord with current
guidelines.
Correct. Non-invasive anatomical imaging with CCTA is one of the recom-
mended options in this case. CCTA should be considered to exclude obstruc-
tive CAD in haemodynamically stable patients with acute chest pain
suggestive of NSTE-ACS, but with initial negative hs-cTn, without ischaemic
ECG changes and low GRACE score (section 3.3). This approach avoids
30% of invasive coronary angiography procedures.
Q29. A 55-year-old woman presents with shortness of
breath, a tight feeling on the chest, and palpitations for 3 h.
In addition, she mentions a few episodes of intermittent
chest discomfort over the last 6 months, lasting minutes
but sometimes hours, occurring both at rest and during
exercise. She has a positive family history for CAD. The ini-
tial ECG demonstrated atrial fibrillation with a heart rate
of 130 bpm and then 96 bpm with no ischaemic changes
after 30 minutes of a resting period. Initial and 1 h hs-cTn
measures were 30 ng/L and 36 ng/L (ULN 14 ng/L), respec-
tively. A resident asks you, as supervisor of the emergency
department/CPU, whether CCTA should be performed
now to rule-out obstructive coronary artery disease.
CCTA has a high diagnostic accuracy for ruling out occlusive CAD. However,
image quality and interpretability may be hampered when irregular heart
rhythm is present. Although elevated levels of hs-cTn may be attributable to
myocardial injury due to rapid ventricular rate response, a CCTA is recom-
mended because of the chest discomfort during the last 6 months and the
positive family history for CAD (section 3.3.5, Figures 3 and 4).
Q30. A just-appointed radiologist challenges the work-up of
patients with acute chest pain by stating the following:
‘Why bother with clinical evaluation, repeated cTn testing,
and ECG assessments in patients with suspected NSTE-
ACS? In the end, all need CCTA’. Is this statement correct?
Not at all. Broad adoption of non-invasive anatomic testing, in terms of
CCTA, among inadequately risk stratified patients, has been shown to
increase downstream testing and costs without clinical benefit for the
patient. In addition, despite the reduction in radiation doses achieved in
recent years, acquisition of high-quality images with low radiation exposure,
as well as appropriate interpretation of CT images, is not usually available
on a 24/7 basis at every institution (section 3.3 and Figures 3 and 4).
Q31. You are on call as a resident in the emergency depart-
ment and you evaluate a 50-year-old woman with new
acute left-sided chest pain without radiation, lasting for 3 h.
She is known for cigarette smoking, hypertension, and
hypercholesterolaemia. The 12-lead ECG and serial meas-
urements of hs-cTn (ESC 0 h/1 h algorithm) are below the
ULN (14 ng/L). The senior cardiologist states that this
patient very likely has unstable angina and she should
therefore undergo early invasive coronary angiography. Is
he right?
No. There is no evidence of severe ischaemia or myocardial necrosis.
Therefore, early invasive coronary angiography is not required. This
patient may have unstable angina, but also non-cardiac causes of
6 ESC Guidelines
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..acute chest pain. CCTA is useful to assess whether this patient has
obstructive CAD (sections 3.3 and 4.3, Figure 3, Figure 4).
Myocardial infarction with
non-obstructed coronary arteries
(MINOCA)
Q32. A 62-year-old woman, former smoker, with no prior
relevant medical history, is admitted to the emergency
department because of a prolonged typical chest pain last-
ing > 6 h. Vital signs are normal except for body tempera-
ture that is 37.6C. The ECG shows 0.5 mm horizontal ST
depression in the anterior and inferior leads. Transthoracic
echocardiography shows borderline left ventricular func-
tion. The first hs-cTn I is 270 ng/L (ULN <14 ng/L). She
immediately receives aspirin and unfractionated heparin
and, a few hours later, undergoes invasive coronary angiog-
raphy which shows no significant stenosis. Your colleague
argues that the problem is microvascular spasm/obstruc-
tion and suggests treating the patient with standard NSTE-
ACS drug therapy. Is he right?
No. MINOCA is a working diagnosis until further assessment
excludes other possible causes for cTn elevation. Intracoronary func-
tional tests (acetylcholine/ergonovine) may be performed when cor-
onary or microvascular spasm is suspected and, in this specific case,
CMR should be performed to exclude myocarditis or specify other
causes for the cTn elevation. Standard NSTE-ACS therapy may not
be the correct choice since pharmacological therapy will vary accord-
ing to the final diagnosis (section 7, Figure 12, Table 14).
Q33. A 70-year-old man, with hypertension and dyslipidae-
mia, presents to the emergency department because of
recurrent episodes of chest pain, not associated with exer-
cise, lasting for a few minutes. At admission, physical
examination is unremarkable. First and second hs-cTn I lev-
els are both within normal range and the first ECG is nor-
mal. Two hours later, the patient has a recurrence of chest
pain with transient ST-segment elevation of 0.5 mm in leads
II, III, and aVF. Immediate invasive coronary angiography is
performed and a mild focal disease on the right coronary
artery and left circumflex artery is found. The fellow tells
you that there is an available slot for CMR in 30 minutes.
Would you do additional invasive tests while waiting for the
CMR?
Clinical history and symptoms suggest that coronary spasms may be the
cause. Therefore, while waiting for CMR to be done, intracoronary functional
tests (acetylcholine/ergonovine) may be performed. Intracoronary imaging
with intravascular ultrasound or optical coherence tomography (OCT) may
also be helpful for the detection of unrecognized plaque ruptures, erosions,
or spontaneous coronary artery dissection (SCAD) (section 7, Figure 12,
Table 14).
Q34. Your fellow is writing the discharge summary of a 70-
year-old woman admitted for recurrent chest pain, positive
hs-cTn I (peak value of 550 ng/L), and normal echocardiog-
raphy. Coronary angiography did not show any significant
lesion. Invasive imaging (OCT) showed some stable plaques
and CMR did not show late gadolinium enhancement. She
is not willing to prescribe any drug after discharge. Do you
agree?
No. Patients with a final diagnosis of MINOCA of unknown cause may be
treated according to secondary prevention guidelines for atherosclerotic dis-
ease. Pharmacological therapy with aspirin and statins is recommended
and angiotensin-converting enzyme inhibitor/angiotensin receptor blocker,
beta-blockers, and calcium channel blockers (in case vasospasm is sus-
pected) may be considered (section 7, Figure 12, Table 14).
Q35. A 45-year-old man comes to your outpatient clinic for
a follow-up visit two weeks after a short hospitalization for
recurrent atypical chest pain with significantly elevated
cTn. Echocardiography shows mild hypokinesia of the mid
and apical segments but invasive coronary angiography is
normal. He is discharged with the recommendation of 12-
months dual antiplatelet therapy (DAPT), statins, and
beta-blockers. CMR is scheduled for 2 months later. What
is your strategy?
This patient was discharged without a complete diagnostic work-up assum-
ing NSTEMI to be the most probable cause of MINOCA. CMR was correctly
indicated to exclude/confirm possible myocarditis and Takotsubo syndrome
but should have been performed earlier to identify the correct diagnosis. It
would be useful, therefore, to perform CMR as soon as possible (section 7,
Figure 12, Table 14).
Q36. A 75-year-old diabetic woman is referred to the emer-
gency department for chest pain associated with intense
and prolonged palpitations a few hours earlier. The ECG
shows sinus rhythm, supraventricular extrasystoles, and no
significant ST-segment changes. The hs-cTn is 180 ng/L
(ULN 14 ng/L) and echocardiography shows a normal left
ventricular ejection fraction and a dilated left atrium.
Invasive coronary angiography performed the following day
is normal. Recurrence of chest pain with concomitant 15
min episodes of high penetrance atrial fibrillation occurs.
Your colleague thinks this MINOCA case should be treated
as an NSTEMI but you disagree.
It is highly probable that symptoms and myocardial injury are related to the
episodes of tachyarrhythmia. It is recommended to manage patients with
an initial diagnosis of MINOCA and a final established underlying cause
according to the disease-specific guidelines. This patient should be treated
according to the atrial fibrillation ESC Guidelines with oral anticoagulation
based on stroke risk assessment and preventive treatments of atrial fibrilla-
tion episodes (section 7, Figure 12, Table 14).
Q37. How would you diagnose and treat a MINOCA patient
suspected for myocarditis that lives in an area where CMR
is not available?
CMR is one of the key diagnostic tools in the MINOCA diagnostic algorithm
for either differential diagnosis of Takotsubo syndrome, myocarditis, or also
true MI. In case intracoronary imaging and the provocative test are negative
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and CMR is not available, patients should undergo echocardiography to
identify left ventricular wall abnormalities, e.g. regional wall motion evalua-
tion, speckle tracking, strain imaging/mapping, real-time myocardial con-
trast, which may help to identify the underlying cause. If myocarditis is still
considered the most probable cause, the patient should be treated accord-
ing to the specific guidelines. If the final diagnosis is MI of unknown/unclear
causes, the pharmacological treatment should follow the secondary preven-
tion guidelines for atherosclerotic disease (section 7, Figure 12, Table 14).
Q38. A 39-year-old woman, of athletic constitution with no
prior relevant medical history, arrives at the emergency
department after experiencing prolonged chest pain while
running. She still has some chest discomfort during the
physical examination, the ECG shows a 1 mm ST depres-
sion in the lateral leads (I-aVL, V5V6), and there is mild
hypokinesia of the lateral wall at echocardiography.
Baseline and 2 h hs-cTn I samples are 450 ng/L and 820 ng/L
(ULN 14 ng/L), respectively. She receives aspirin and
unfractionated heparin and is sent to the catheterization
lab. Invasive coronary angiography shows some contrast
dye staining with a multiple radiolucent lumen of the
obtuse marginal branch with preserved coronary flow. Your
colleague suggests treating this patient with coronary
stenting and 12-month DAPT. Is he right?
According to the available data, apart from very high-risk profile patients, a
conservative approach should be the preferred strategy in type I SCAD with
no coronary obstructions and preserved coronary flow. Optimal medical
treatment is still undetermined but because hypertension is an independent
predictor of recurrent SCAD, hypertensive therapy should be considered
and beta-blockers should be the first choice in this subset of patients. The
benefit of antithrombotic therapy among these patients is still controversial.
In selected patients, invasive coronary angiography or CCTA may be consid-
ered as follow-up in addition to clinical visits (section 6.1.5, Figure 11).
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